Eric has a strong multidisciplinary background in metabolic disease and oncology targets with over 20 years of experience in the biotech/pharmaceutical industry. Prior to joining RayzeBio, he served as Vice President Development & Operations at Metacrine, Inc. a mid-stage clinical development company where he oversaw nonclinical development of the lead clinical assets for non-alcoholic steatohepatitis (NASH). Prior to Metacrine, he served as Senior Director of Operations at Seragon Pharmaceuticals and was involved in business development efforts resulting in the $1.7B acquisition of Seragon by Genentech, for an upfront payment of $725M and $1B in contingent development milestones. Prior to Ser agon, he served as Director of Operations at Aragon Pharmaceuticals on the development of apalutamide which was successfully commercialized following Aragon’s acquisition by Johnson & Johnson for $1B. In previous positions, Eric worked as a pharmacologist with numerous scientific publications on oncology and metabolic disease targets at companies including X-Ceptor Therapeutics, acquired by Exelixis, Ligand Pharmaceuticals and Hybritech, Inc. Eric is a graduate of the University of California at San Diego.
Current role
SVP, Development Operations at Cytokinetics
SVP, Development Operations at Vera Therapeutics
SVP, Development Operations at Pliant Therapeutics
SVP, Development Operations at VistaGen Therapeutics
SVP, Development & Operations at SolarBioTech